Search bioRxiv⌕ Search

Biology subjects

Massignani, E.

Publications and source records attributed to Massignani, E..

6 recordsLinked to original sources

Discovery of non-canonical proteins through modification-aware proteogenomics

ShortThe SwissProt database contains a stable 20,418 human protein-coding genes and 42,541 human protein sequences. Ribo-Seq suggests about 7,000 additional, non-canonical Open Reading Frames (ORFs) are present in humans, though only a few of them are confirmed by Mass Spectrometry (MS). Detecting these proteins requires extensive database searches, increasing computational load and inflating False Discovery Rates (FDR). Using the ionbot search engine with the OpenProt database allows for reliable detection of non-canonical proteins while controlling FDR. Ionbot surpasses the Trans-Proteomics Pipeline (TPP) in reproducibility, identifying more peptides and proteins supported by multiple spectra. In addition, open modification searches yield better PSMs compared to closed searches. This work highlights the importance of employing cutting-edge search engines in non-canonical protein research, as well as the value of open modification search in correcting errors in non-canonical protein detection. LongO_ST_ABSBackgroundC_ST_ABSThe SwissProt database reports a quite stable 20,418 human protein-coding genes and 42,541 human protein sequences, figures that have remained stable. New techniques like Ribo-Seq indicate that approximately 7,000 additional, non-canonical Open Reading Frames (ORFs) are translated in humans, few of which have been confirmed by Mass Spectrometry (MS). Detecting these non-canonical proteins requires comprehensive database searches, which increase computational load and False Discovery Rate (FDR). Here, we use the open search engine ionbot in combination with the OpenProt proteogenomics database to reproducibly detect non-canonical proteins while maintaining a well-controlled FDR. ResultsCompared to the current gold standard, the Trans-Proteomics Pipeline (TPP), ionbot shows higher reproducibility, with a higher number of peptides and proteins supported by multiple spectra, and across multiple samples. We observe that PSMs from the open modification search against OpenProt have higher fragment ion intensity correlation compared to PSMs obtained from the closed search, or by only searching canonical proteins. ConclusionsIn this work, we show the potential for open modification searching to correct potential mistakes in non-canonical proteins detection by preventing modified canonical peptides or variants from being incorrectly identified as non-canonical peptides. We also highlight the importance of assessing the FDR of non-canonical identifications separately from canonical ones, as global FDR calculations are biased by the scarcity of non-canonical identifications in each dataset.

molecular biology↗

Scop3P in 2026: an expanded proteomics-informed resource contextualizing phosphorylation sites through sequence, structure, mutation, and experimental provenance

Protein phosphorylation is a central regulatory mechanism controlling protein activity, interactions, and cellular signalling, and its dysregulation is implicated in numerous diseases. Advances in mass spectrometry-based phosphoproteomics have led to a rapid expansion in the number of reported phosphorylation sites; however, interpretation of these data remains challenging due to fragmented evidence, limited structural context, and the lack of uniform experimental provenance across resources. Interpretation is further complicated by the fact that the biological meaning of reported phosphosites can vary substantially across tissues, cell lines, perturbations, and disease settings. Here, we present a major update of Scop3P, a proteomics-informed knowledgebase that contextualizes human phosphorylation sites within integrated sequence, structural, biophysical, evolutionary, and mutational frameworks. The current release incorporates uniformly reprocessed human phosphoproteomics data from 116 PRIDE datasets alongside curated UniProt annotations, retaining peptide-spectrum matches, site localization confidence, and direct links to primary mass spectrometry evidence via Universal Spectrum Identifiers. This integration yields 152,350 unique serine, threonine, and tyrosine phosphorylation sites across 16,533 human proteins, supported by full experimental provenance. Beyond site identification, Scop3P provides residue-level contextual annotations derived from experimentally determined protein structures and proteome-wide AlphaFold models, enabling near-complete structural coverage of phosphorylation sites. Structural context is further complemented by residue-level biophysical, evolutionary, and mutational annotations, supporting integrated assessment of phosphorylation in functional and disease-related settings. The current release also introduces residue interaction network representations derived from AlphaFold-predicted structures, capturing spatial connectivity and local interaction environments of phosphorylation and mutation sites. A redesigned web interface enables interactive exploration through coordinated 1D, 2D, 2.5D, and 3D visualizations, peptide-level coverage views, and direct access to original spectra via PRIDE. By bridging experimental phosphoproteomics with structural, functional, and disease-related context, Scop3P provides a scalable and provenance-aware resource for phosphosite interpretation, hypothesis generation, and data-driven modelling of phosphorylation-dependent regulation.

bioinformatics↗

MoDPA: Inferring Modification-dependent Protein Associations from Uniformly Reprocessed Mass Spectrometry

MotivationPost-translational modifications (PTMs) are key regulators of protein function and cellular processes; however, the overall principles of PTM co-regulation and crosstalk remain to be fully understood. A major challenge in large-scale PTM crosstalk studies is the scarcity of data, which hampers the ability to reproducibly detect proteome-wide associations between modification sites. ResultsWe present a new computational framework, named Modification-Dependent Protein Associations (MoDPA). To overcome the extreme sparsity and heterogeneity of PTM calls across experiments, MoDPA utilizes a variational autoencoder (VAE) to embed per-site detection profiles into a low-dimensional latent space that preserves covariation while denoising missing data. A PTM association network is constructed by correlating latent representations across experiments. Benchmarking against pulsed SILAC data shows that MoDPA can correctly capture the correlation between heavy- and light-labelled peptides. We apply MoDPA to a large sample of reprocessed public datasets and identify clusters of modified proteins involved in distinct biological pathways, suggesting that some modifications may preferentially regulate specific biological processes, but not others. In particular, we find clusters enriched in lysine acetylation, lysine methylation, and arginine deamidation (citrullination) sites, which contain proteins involved in protein synthesis, neuron development, and cellular senescence. Availability and ImplementationAll code is freely available on GitHub (https://github.com/CompOmics/MoDPAv1.0) and Zenodo (10.5281/zenodo.18310674). The resulting MoDPA-derived PTM network is available via the TabloidProteome website at https://iomics.ugent.be/tabloidproteome. Contactenrico.massignani@ugent.be, lennart.martens@ugent.be

bioinformatics↗

ProMetheusDB: an in-depth analysis of the high-quality human methyl-proteome

Protein Arginine (R) methylation is a post-translational modification involved in various biological processes, such as RNA splicing, DNA repair, immune response, signal transduction, and tumour development. Although several advancements were made in the study of this modification by mass spectrometry, researchers still face the problem of a high false discovery rate. We present a dataset of high-quality methylations obtained from several different heavy methyl SILAC (hmSILAC) experiments analysed with a machine learning-based tool doublets and show that this model allows for improved high-confidence identification of real methyl-peptides. Overall, our results are consistent with the notion that protein R methylation modulates protein:RNA interactions and suggest a role in rewiring protein:protein interactions, for which we provide experimental evidence for a representative case (i.e. NONO:PSPC1). Upon intersecting our R-methyl-sites dataset with a phosphosites dataset, we observed that R methylation correlates differently with S/T-Y phosphorylation in response to various stimuli. Finally, we explored the application of hmSILAC to identify unconventional methylated residues and successfully identified novel histone methylation marks on Serine 28 and Threonine 32 of H3.

bioinformatics↗

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1, a novel oncogene in AML

The histone de-methylase LSD1 is over-expressed in haematological tumours and has emerged as a promising target for anti-cancer treatment, so that several LSD1 inhibitors are under development and testing, in pre-clinical and clinical settings. However, the complete understanding of their complex mechanism of action is still unreached. Here, we unravelled a novel mode of action of the LSD1 inhibitors MC2580 and DDP-38003, showing that they can induce differentiation of AML cells through the down-regulation of the chromatin protein GSE1. Analysis of the phenotypic effects of GSE1 depletion in NB4 cells showed a strong decrease of cell viability in vitro and of tumour growth in vivo. Mechanistically, we found that a set of genes associated with immune response and cytokine signalling pathways are up-regulated by LSD1 inhibitors through GSE1 protein reduction and that LSD1 and GSE1 co-localise at promoters of a subset of these genes at the basal state, enforcing their transcriptional silencing. Moreover, we show that LSD1 inhibitors lead to the reduced binding of GSE1 to these promoters, activating transcriptional programs that trigger myeloid differentiation. Our study offers new insights on GSE1 as a novel therapeutic target for AML.

cancer biology↗

PRMT1-mediated methylation of the Large Drosha Complex regulates microRNA biogenesis

MicroRNA (miRNA) biogenesis is a tightly controlled multi-step process operated in the nucleus by the activity of the Large Drosha Complex (LDC). Through high resolution mass spectrometry (MS) analysis we discovered that the LDC is extensively methylated, with 82 distinct methylated sites associated to 16 out of 23 subunits of the LDC. The majority of these modifications occurs on arginine (R)- residues (61), leading to 86 methylation events, while 29 lysine (K)-methylation events occurs on 21 sites of the complex. Interestingly, both depletion and pharmacological inhibition of PRMT1 lead to a widespread alteration of the methylation state of the complex and induce global decrease of miRNA expression, as a consequence of the specific impairment of the pri-to-pre-miRNA processing step. In particular, we show that the reduced methylation of the ILF3 subunit of the complex is linked to its diminished binding to the target pri-miRNAs. Overall, our study uncovers a previously uncharacterized role of R-methylation in the regulation of the LDC activity in mammalian cells, thus affecting global miRNA levels.

cell biology↗